Memantine Mylan
Analogs of Memantine Mylan
Find cheaper analogs and generic equivalents for Memantine Mylan.
Active Ingredient: memantine hydrochloride
Product Overview
About Memantine Mylan
Memantine Mylan is a generic medicine similar to a reference medicine already authorised in the EU called Ebixa.
What it is used for
Memantine Mylan is used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia that gradually affects memory, intellectual ability and behaviour.
How it is used
Memantine Mylan is available as 10-mg and 20-mg tablets and can only be obtained with a prescription. Treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease. Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Mylan by the patient. Memantine Mylan should be given once a day at the same time every day. To prevent side effects, the dose of Memantine Mylan is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day. The tolerance and dose should be assessed within three months after starting treatment, and from then on the benefits of continuing treatment with Memantine Mylan should be reassessed on a regular basis. The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.
How it works
The active substance in Memantine Mylan, memantine, is an antidementia medicine. The cause of Alzheimer’s disease is unknown, but memory loss in the disease is believed to be due to a disturbance of message signals in the brain. Memantine works by blocking special types of receptor called N-methyl-D-aspartate (NMDA) receptors to which the neurotransmitter glutamate normally attaches.
Active substance: memantine
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
